Pre-emptive morphine treatment abolishes nerve injury-induced lysophospholipid synthesis in mass spectrometrical analysis

Journal of Neurochemistry

Volumn 118, Issue 2, 2011, Pages 256-265

  Nagai, Jun ^a   Ueda, Hiroshi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

autotaxin; lysophosphatidyl choline; mass spectrometry; morphine; neuropathic pain; pre emptive analgesia

Indexed keywords

AUTOTAXIN; LYSOPHOSPHATIDYLCHOLINE; MORPHINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DORSAL ROOT; DRUG TARGETING; LIPID ANALYSIS; MALE; MASS SPECTROMETRY; MOUSE; NANOSTRUCTURE ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NERVE INJURY; NOCICEPTION; NONHUMAN; PHOSPHOLIPID SYNTHESIS; PRIORITY JOURNAL; QUANTITATIVE STUDY; SCIATIC NERVE; SIGNAL DETECTION; SPINAL CORD; WILD TYPE;

ANIMALS; LYSOPHOSPHATIDYLCHOLINES; LYSOPHOSPHOLIPIDS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MORPHINE; SCIATIC NEUROPATHY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TREATMENT OUTCOME;

MUS;

EID: 80955179997     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2011.07297.x     Document Type: Article

References (41)

1. Aoki J., Inoue A., and, Okudaira S., (2008) Two pathways for lysophosphatidic acid production. Biochim. Biophys. Acta 1781, 513-518.
2. Basbaum A. I., and, Fields H. L., (1979) The origin of descending pathways in the dorsolateral funiculus of the spinal cord of the cat and rat: further studies on the anatomy of pain modulation. J. Comp. Neurol. 187, 513-531. (Pubitemid 10220197)
3. Bligh E. G., and, Dyer W. J., (1959) A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37, 911-917.
4. Choi J. W., Herr D. R., Noguchi K., et al. (2010) LPA receptors: subtypes and biological actions. Annu. Rev. Pharmacol. Toxicol. 50, 157-186.
5. Chun J., Hla T., Lynch K. R., Spiegel S., and, Moolenaar W. H., (2010) International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol. Rev. 62, 579-587.
6. Fields H. L., Basbaum A. I., and, Heinricher M. M,. (2006) Central nervous system mechanisms of pain modulation, in Wall and Melzack's Textbook of Pain (, McMahon S. B., and, Koltzenburg M., eds), pp. 125-142. Elsevier Churchill Livingstone, Philadelphia.
7. Hsu F. F., and, Turk J., (2003) Electrospray ionization/tandem quadrupole mass spectrometric studies on phosphatidylcholines: the fragmentation processes. J. Am. Soc. Mass Spectrom. 14, 352-363. (Pubitemid 36876036)
8. Inoue M., Rashid M. H., Fujita R., Contos J. J., Chun J., and, Ueda H., (2004) Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat. Med. 10, 712-718. (Pubitemid 38937636)
9. Inoue M., Ma L., Aoki J., Chun J., and, Ueda H., (2008a) Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain. Mol. Pain 4, 6.
10. Inoue M., Ma L., Aoki J., and, Ueda H., (2008b) Simultaneous stimulation of spinal NK1 and NMDA receptors produces LPC which undergoes ATX-mediated conversion to LPA, an initiator of neuropathic pain. J. Neurochem. 107, 1556-1565.
11. Koizumi S., Yamamoto S., Hayasaka T., Konishi Y., Yamaguchi-Okada M., Goto-Inoue N., Sugiura Y., Setou M., and, Namba H., (2010) Imaging mass spectrometry revealed the production of lyso-phosphatidylcholine in the injured ischemic rat brain. Neuroscience 168, 219-225.
12. Lin M. E., Herr D. R., and, Chun J., (2010) Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat. 91, 130-138.
13. Ma L., Matsumoto M., Xie W., Inoue M., and, Ueda H., (2009a) Evidence for lysophosphatidic acid 1 receptor signaling in the early phase of neuropathic pain mechanisms in experiments using Ki-16425, a lysophosphatidic acid 1 receptor antagonist. J. Neurochem. 109, 603-610.
14. Ma L., Uchida H., Nagai J., Inoue M., Chun J., Aoki J., and, Ueda H., (2009b) Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain. Mol. Pain 5, 64.
15. Ma L., Nagai J., and, Ueda H., (2010a) Microglial activation mediates de novo lysophosphatidic acid production in a model of neuropathic pain. J. Neurochem. 115, 643-653.
16. Ma L., Uchida H., Nagai J., Inoue M., Aoki J., and, Ueda H., (2010b) Evidence for de novo synthesis of lysophosphatidic acid in the spinal cord through phospholipase A2 and autotaxin in nerve injury-induced neuropathic pain. J. Pharmacol. Exp. Ther. 333, 540-546.
17. Malmberg A. B., and, Basbaum A. I., (1998) Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates. Pain 76, 215-222. (Pubitemid 28304959)
18. Milligan E. D., and, Watkins L. R., (2009) Pathological and protective roles of glia in chronic pain. Nat. Rev. Neurosci. 10, 23-36.
19. Morishige J., Urikura M., Takagi H., Hirano K., Koike T., Tanaka T., and, Satouchi K., (2010) A clean-up technology for the simultaneous determination of lysophosphatidic acid and sphingosine-1-phosphate by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using a phosphate-capture molecule, Phos-tag. Rapid Commun. Mass Spectrom. 24, 1075-1084.
20. Nagai J., Uchida H., Matsushita Y., Yano R., Ueda M., Niwa M., Aoki J., Chun J., and, Ueda H., (2010) Autotaxin and lysophosphatidic acid1 receptor-mediated demyelination of dorsal root fibers by sciatic nerve injury and intrathecal lysophosphatidylcholine. Mol. Pain 6, 78.
21. Nakamura K., Ohkawa R., Okubo S., et al. (2009) Autotaxin enzyme immunoassay in human cerebrospinal fluid samples. Clin. Chim. Acta 405, 160-162.
22. Navarro X., Vivo M., and, Valero-Cabre A., (2007) Neural plasticity after peripheral nerve injury and regeneration. Prog. Neurobiol. 82, 163-201. (Pubitemid 47088051)
23. Noguchi K., Herr D., Mutoh T., and, Chun J., (2009) Lysophosphatidic acid (LPA) and its receptors. Curr. Opin. Pharmacol. 9, 15-23.
24. Pulfer M., and, Murphy R. C., (2003) Electrospray mass spectrometry of phospholipids. Mass Spectrom. Rev. 22, 332-364.
25. Rashid M. H., and, Ueda H., (2005) Pre-injury administration of morphine prevents development of neuropathic hyperalgesia through activation of descending monoaminergic mechanisms in the spinal cord in mice. Mol. Pain 1, 19.
26. Richmond C. E., Bromley L. M., and, Woolf C. J., (1993) Preoperative morphine pre-empts postoperative pain. Lancet 342, 73-75. (Pubitemid 23192422)
27. Sato M., and, Takagi H., (1971) Enhancement by morphine of the central descending inhibitory influence on spinal sensory transmission. Eur. J. Pharmacol. 14, 60-65.
28. Scholz J., and, Woolf C. J., (2007) The neuropathic pain triad: neurons, immune cells and glia. Nat. Neurosci. 10, 1361-1368. (Pubitemid 350014681)
29. Sutphen R., Xu Y., Wilbanks G. D., et al. (2004) Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 13, 1185-1191. (Pubitemid 38917907)
30. Takatera A., Takeuchi A., Saiki K., Morisawa T., Yokoyama N., and, Matsuo M., (2006) Quantification of lysophosphatidylcholines and phosphatidylcholines using liquid chromatography-tandem mass spectrometry in neonatal serum. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 838, 31-36. (Pubitemid 43832208)
31. Tanaka T., Tsutsui H., Hirano K., Koike T., Tokumura A., and, Satouchi K., (2004) Quantitative analysis of lysophosphatidic acid by time-of-flight mass spectrometry using a phosphate-capture molecule. J. Lipid Res. 45, 2145-2150. (Pubitemid 40990911)
32. Tanaka M., Okudaira S., Kishi Y., et al. (2006) Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J. Biol. Chem. 281, 25822-25830. (Pubitemid 44401970)
33. Tokumura A., (2002) Physiological and pathophysiological roles of lysophosphatidic acids produced by secretory lysophospholipase D in body fluids. Biochim. Biophys. Acta 1582, 18-25. (Pubitemid 34634107)
34. Uchida H., Ma L., and, Ueda H., (2010) Epigenetic gene silencing underlies C-fiber dysfunctions in neuropathic pain. J. Neurosci. 30, 4806-4814.
35. Ueda H., (2006) Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms. Pharmacol. Ther. 109, 57-77. (Pubitemid 41740815)
36. Ueda H., (2008) Peripheral mechanisms of neuropathic pain-involvement of lysophosphatidic acid receptor-mediated demyelination. Mol. Pain 4, 11.
37. Ueda H,. (2011) Lysophosphatidic acid as initiator of neuropathic pain-biosynthesis and demyelination. Clin. Lipidol. 6, 147-158.
38. Wyatt M. F., Ding S., Stein B. K., Brenton A. G., and, Daniels R. H., (2010) Analysis of various organic and organometallic compounds using nanostructure-assisted laser desorption/ionization time-of-flight mass spectrometry (NALDI-TOFMS). J. Am. Soc. Mass Spectrom. 21, 1256-1259.
39. Yamashita A., Sugiura T., and, Waku K., (1997) Acyltransferases and transacylases involved in fatty acid remodeling of phospholipids and metabolism of bioactive lipids in mammalian cells. J. Biochem. 122, 1-16. (Pubitemid 27346216)
40. Zhuo M., (2007) A synaptic model for pain: long-term potentiation in the anterior cingulate cortex. Mol. Cells 23, 259-271. (Pubitemid 47181042)
41. Zimmermann M., (1983) Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16, 109-110. (Pubitemid 13058546)